Synthesis and biological evaluation of benzodioxanylpiperazine derivatives as potent serotonin 5-HT1A antagonists? The discovery of Lecozotan

Journal of Medicinal Chemistry

Volumn 48, Issue 10, 2005, Pages 3467-3470

  Childers Jr , Wayne E ^a   Abou Gharbia, Magid A ^a   Kelly, Michael G ^a,b   Andree, Terrance H ^a   Harrison, Boyd L ^a   Ho, Douglas M ^a,d   Hornby, Geoffrey ^a   Huryn, Donna M ^a   Potestio, Lisa ^a   Rosenzweig Lipson, Sharon J ^a   Schmid, Jean ^a   Smith, Deborah L ^a   Sukoff, Stacey J ^a   Zhang, Gan ^a,c   Schechter, Lee E ^a  

^a PFIZER INC   (United States)

^b EVOTEC AG   (Germany)

^c ARRAY BIOPHARMA INC   (United States)

^d PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LECOZOTAN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CRYSTALLOGRAPHY, X-RAY; CYCLIC AMP; DIOXANES; GTP-BINDING PROTEINS; HUMANS; MOLECULAR STRUCTURE; PIPERAZINES; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT1A; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 20844444611     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049493z     Document Type: Article

References (32)

1. 3H] 5-Hydroxytryptamine Binding Sites by the Neuroloptic Spiperone in Rat Brain. J. Neurochem. 1981, 36, 220-226.
2. 1A Receptor. Nature 1988, 335, 358-360.
3. Chanda, P. K.; Minchin, M. C. W.; Davis, A. R.; Greenberg, L.; Reilly, Y.; McGregor, W. H.; Bhat, R.; Lubeck, M. D.; Mizutani, S.; Huang, P. P. Identification of Residues Important for Ligand Binding to the Human 5-Hydroxytryptamine1A Serotonin Receptor. Mol. Pharmacol. 1993, 43, 516-520.
4. Kobilka, B. K.; Frielle, T.; Collins, S.; Yang-Feng, T.; Kobilka, T. S.; Francke, U.; Lefkowitz, R. J.; Caron, M. G. An Intronless Gene Encoding a Potential Member of the Family of Receptors Coupled to Guanine Nucleotide Regulatory Proteins. Nature 1987, 329, 75-79.
5. Pazos, A.; Palacios, J. M. Quantitative Autoradiographic Mapping of Serotonin Receptors in the Rat Brain. I. Serotonin-1 Receptors. Brain Res. 1985, 346, 205-230.
6. 1A-Mediated Inhibition of Serotonin Synthesis: Possible Relationship to Anxiolytic Properties of 5-Hydroxytryptamine1A Agonists. Mol. Pharmacol. 1990, 37, 231-237.
7. 1A Agonists. Synapse 1993, 14, 297-304.
8. 1 Recognition Site. Eur. J. Pharmacol. 1983, 90, 151-153.
9. 1A Receptor Antagonists NAN-190 and BMY 7378 Are Partial Agonists in the Rat Dorsal Raphe Nucleus In Vitro. Eur. J. Pharmacol. 1992, 211, 211-219.
10. 1A Receptor Antagonist. J. Med. Chem. 1990, 33, 1541-1544.
11. 1A Receptor Antagonist (S)-5-Fluoro-8-hydroxy-2-(dipropylamino) tetralin: Inhibition of (R)-8-Hydroxy-2-(dipropylamino)tetralin-Induced Effects. J. Pharmacol. Exp. Ther. 1991, 258, 58-65.
12. 1A Receptor Antagonist WAY-100635. Eur. J. Pharmacol. 1995, 281, 81-88.
13. 1A Antagonist LY426965: Effects on Nicotine Withdrawal and Interactions with Fluoxetine. J. Pharmacol. Exp. Ther. 2000, 294, 688-700.
14. Mucke, H., Robalzotan. In The Investigational Drugs Database (IDdb3), Thompson Current Drugs, March 24, 2004.
15. 1A Receptor Antagonists: Historical Perspective and Therapeutic Targets. Serotonin ID Res. Alert 1997, 2, 299-309.
16. 1A Autoreceptor Blockade Potentiates the Ability of the 5-HT Re-uptake Inhibitor Citalopram to Increase nerve Terminal Output of 5-HT In Vivo: A Microdialysis Study. J. Neurochem. 1993, 60, 776-779.
17. 1A Receptor Antagonist and an SSRI In Vivo: Effects on 5-HT Cell Firing and Extracellular 5-HT. Br. J. Pharmacol. 1995, 115, 1064-1070.
18. 1A Receptor Antagonists in Combination with Paroxetine on Expression of the Immediate-Early Gene Arc in Rat Brain. Neuropharmacology 2003, 44, 893-902.
19. Artigas, F.; Perez, V.; Alvarez, E. Pindolol Induces a Rapid Improvement of Depressed Patients Treated with Serotonin Reuptake Inhibitors. Arch. Gen. Psychiatry 1994, 51, 248-251.
20. Blier, P.; Bergeron, R. Effectiveness of Pindolol with Selected Antidepressant Drugs in the Treatment of Major Depression. J. Clin. Psychopharmacol. 1995, 15, 217-222.
21. Berman, R. M.; Darnell, A. M.; Miller, H. L.; Anand, A.; Charney, D. S. Effect of Pindolol in Hastening Response to Fluoxetine in the Treatment of Major Depression: A Double-Blind, Placebo-Controlled Trial. Am. J. Psychiatry 1997, 154, 37-43.
22. 1A Receptor Antagonists in the Treatment of Cognitive Dysfunction Associated with Alzheimer's Disease. Curr. Pharm. Des. 2002, 8, 139-145.
23. Abou-Gharbia, M.; Moyer, J.; Haskins, J. T. WY-47,846. Drugs Future 1989, 14, 442-443.
24. 2 Activity as Potential Anxiolytic and Antidepressant Agents. J. Med. Chem. 1999, 42, 5077-5094.
25. Brightwell, C. I.; Shepherd, R. G. Novel Processes and Intermediates for the Preparation of Piperazine Derivatives. PCT Application WO 9533725, 1995.
26. Hartog, J.; Wouters, W.; van Wijngaarden, I. Blood Pressure-Lowering Piperazine Derivatives. EP 138280 B1, 1985.
27. 1A Receptor as Assessed with the Cytosensor Microphysiometer. J. Pharmacol. Tox. Methods 1998, 40, 47-55.
28. 1A Antagonist Research. Drugs Future 1993, 18, 631-642;
29. 1A Receptor Modulators. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press: New York, 1995; Vol. 30, pp 1-9.
30. Lazareno, S.; Birdsall, N. J. Pharmacological Characterization of Acetylcholine-Stimulated [35S]-GTPγS Binding Mediated by Human Muscarinic m1-m4 Receptors: Antagonist Studies. Br. J. Pharmacol. 1993, 109, 1120-1127.
31. Blackman, D. Operant Conditioning: An Experimental Analysis of Behavior. In Methuen's Manuals of Psychology; Butcher, J., Ed.; Methuen & Co., Ltd.: London; 1974.
32. 1A Compounds Varying in Intrinsic Activity. Soc. Neurosci. 1997, 23, 134.